Verastem PE Ratio 2011-2021 | VSTM

Current and historical p/e ratio for Verastem (VSTM) from 2011 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Verastem PE ratio as of October 26, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Verastem PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-27 2.59 0.00
2021-06-30 4.07 $-0.23 0.00
2021-03-31 2.47 $-0.27 0.00
2020-12-31 2.13 $-0.53 0.00
2020-09-30 1.21 $-0.92 0.00
2020-06-30 1.72 $-1.41 0.00
2020-03-31 2.64 $-1.84 0.00
2019-12-31 1.34 $-2.01 0.00
2019-09-30 1.21 $-1.87 0.00
2019-06-30 1.51 $-1.75 0.00
2019-03-31 2.96 $-1.48 0.00
2018-12-31 3.36 $-1.37 0.00
2018-09-30 7.25 $-1.43 0.00
2018-06-30 6.88 $-1.75 0.00
2018-03-31 2.98 $-1.81 0.00
2017-12-31 3.07 $-1.75 0.00
2017-09-30 4.70 $-1.64 0.00
2017-06-30 2.18 $-1.24 0.00
2017-03-31 2.07 $-1.11 0.00
2016-12-31 1.12 $-0.98 0.00
2016-09-30 1.33 $-0.98 0.00
2016-06-30 1.30 $-1.19 0.00
2016-03-31 1.58 $-1.38 0.00
2015-12-31 1.86 $-1.62 0.00
2015-09-30 1.79 $-1.83 0.00
2015-06-30 7.54 $-1.93 0.00
2015-03-31 10.17 $-2.02 0.00
2014-12-31 9.14 $-2.07 0.00
2014-09-30 8.52 $-1.99 0.00
2014-06-30 9.06 $-1.94 0.00
2014-03-31 10.79 $-1.92 0.00
2013-12-31 11.40 $-1.85 0.00
2013-09-30 12.45 $-1.79 0.00
2013-06-30 13.88 $-1.83 0.00
2013-03-31 9.62 $-1.68 0.00
2012-12-31 8.79 $-1.71 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.472B $0.089B
Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86